title: Cardiac effects of clinically available Kampo medicine assessed with canine isolated, blood-perfused heart preparations.
abstract: Cardiac effects of 10 kinds of clinically available Kampo medicines were investigated: Kakkon-to (TJ-1), Dai-saiko-to (TJ-8), Boi-ogi-to (TJ-20), Chorei-to (TJ-40), Rokumi-gan (TJ-87), Tsu-do-san (TJ-105), Gosha-jinki-gan (TJ-107), San'o-shashin-to (TJ-113), Sairei-to (TJ-114) and Inchin-gorei-san (TJ-117). Chronotropic and inotropic effects were studied using canine isolated, blood-perfused heart preparations, while subcellular mechanisms were analyzed by measuring the drug-induced changes of the adenylate cyclase activity in the canine ventricular membrane preparation. Intracoronary injections of TJ-1, TJ-20, TJ-105 and TJ-113 increased the sinoatrial rate and developed tension of papillary muscle in a dose-related manner, which was significantly attenuated by the pretreatment of the preparations with beta-blocker propranolol. Meanwhile, the other extracts hardly affected these parameters. TJ-1, TJ-20 and TJ-113 increased the adenylate cyclase activity in a dose-related manner, but their potency was significantly less compared with that by an equivalent concentration of isoproterenol. Moreover, TJ-105 did not increase the adenylate cyclase activity. These results suggest that the positive chronotropic and inotropic effects of TJ-1, TJ-20, TJ- 105 and TJ-113 may be exerted through the direct stimulation of the beta-adrenoceptor and/or the norepinephrine release from the postganglionic nerve terminals in the heart.
authors.affiliation: Department of Pharmacology, Yamanashi Medical University, Nakakoma-gun, Japan. atsushis@res.yamanashi-med.ac.jp
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sugiyama
authors.forename: Akira
authors.initials: A
authors.lastname: Takahara
authors.forename: Yoshioki
authors.initials: Y
authors.lastname: Satoh
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yoneyama
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Saegusa
authors.forename: Keitaro
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001803:Blood Transfusion; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002462:Cell Membrane / Q000201:enzymology; D003427:Cross Circulation; D004285:Dogs; D006321:Heart / Q000187:drug effects*; D006352:Heart Ventricles / Q000187:drug effects; D006706:Homeostasis / Q000187:drug effects; D066298:In Vitro Techniques; D020835:Medicine, Kampo; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000201:enzymology; D010477:Perfusion; D011433:Propranolol / Q000494:pharmacology; D012849:Sinoatrial Node / Q000187:drug effects; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism
chemical_list: D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents; D011433:Propranolol; D000262:Adenylyl Cyclases